OneMedNet Corp (ONMD): Cash & Equivalents

Annual figures by period end, from SEC filings.

$585.0K
As of 2025-12-31
$358.0K
As of 2026-06-30
+29.2%
3-year compound annual growth
2021-12-31: $453.2K2022-12-31: $271.0K2023-12-31: $47.0K2024-12-31: $172.0K2025-12-31: $585.0K$585.0K
2021-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$585.0K+240.1%2026-03-30, Balance as of period end
2024-12-31$172.0K+266.0%2026-03-30, Balance as of period end
2023-12-31$47.0K-82.7%2025-04-15, Balance as of period end
2022-12-31$271.0K-40.2%2024-11-05, Balance as of period end
2021-12-31$453.2Kn/a2023-03-31, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
OneMedNet Corp (ONMD)2025-12-31$585.0K+240.1%
iSpecimen Inc. (ISPC)2025-12-31$6.88M+266.3%
Absci Corp (ABSI)2025-12-31$20.02M-51.4%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$6.45M+483.5%
Foxo Technologies Inc. (FOXO)2025-12-31$207.5K+203.9%
OmniAb, Inc. (OABI)2025-12-31$25.52M-7.5%
MaxCyte, Inc. (MXCT)2025-12-31$20.07M-28.0%
NRC Health (NRC)2025-12-31$4.14M-2.2%
Medpace Holdings, Inc. (MEDP)2025-12-31$497.05M-25.8%

Compare ONMD, ISPC, ABSI, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗